The online version of this article (doi:10.1186/s13045-017-0427-x) contains supplementary material, which is available to authorized users.
Presented in abstract form as an oral presentation at the 57th annual meeting of the American Society of Hematology, Orlando, FL, 7 December 2015.
Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin internalization, restore iron efflux from cells, and allow transferrin-mediated iron transport to the bone marrow. This multicenter, phase 1 study evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of a fully humanized mAb (LY2787106) with high affinity for hepcidin in cancer patients with anemia.
Thirty-three patients with hepcidin levels ≥5 ng/mL received LY2787106 either every 3 weeks (19 patients, dose range 0.3–10 mg/kg) (part A) or weekly (14 patients, dose 10 mg/kg) (part B). LY2787106 PK/PD markers of iron and hematology biology were measured.
LY2787106 clearance (32 mL/h) and volume of distribution (7.7 L) were independent of dose and time, leading to a dose-proportional increase in concentration with dose. Consistent dose-dependent increases in serum iron, and transferrin saturation were seen at the 3 and 10 mg/kg dose levels, typically peaking within 24 h after LY2787106 administration and returning to baseline by day 8.
Our findings indicate that LY2787106 was well tolerated in cancer patients with anemia and that targeting the hepcidin-ferroportin pathway by neutralizing hepcidin resulted in transient iron mobilization, thus supporting the role of hepcidin in iron regulation.
Additional file 1: Inclusion Criteria. Exclusion Criteria. Stopping Rules. Figure S1. Changes in (A) serum iron and (B) transferrin saturation from baseline in 3- and 10-mg/kg dosing cohorts in part A, as determined at interim analysis before start of part B. (DOCX 336 kb)13045_2017_427_MOESM1_ESM.docx
Arvedson TC, Li H, Rose MJ, Wang O, Sasu BJ. Evaluation of serum hepcidin concentrations in cancer and leukemia patients [abstract]. J Clin Oncol. 2008;26(15S):20581. CrossRef
Boyce M, Warrington S, Cortezi B, Zöllner S, Vauléon S, Swinkels DW, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016. doi: 10.1111/bph.13433.
Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836(2):245–54. PubMed
- A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Jonathan W. Goldman
David A. Smith
Christopher A. Slapak
Robert L. Ilaria Jr
Ramon V. Tiu
Jay L. Tuttle
Eric J. Roeland
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II